Company: IMRX
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0001790340-25-000042
Chunk: 111

Company: Immuneering Corp
Filing Date: 2025-03-20
Form: 10-K
Item: Item 8
Chunk 111
---
31,930,000 52,300,000 Net cash provided by investing activities26,434,955 7,296,492 Cash flows from financing activities:Proceeds from public offering of common stock, net of commissions and underwriting — 28,200,003 Payment of public offering costs(40,988)(203,768)Proceeds from exercise of stock options732,458 444,838 Proceeds from issuance of common stock under ATM, net of offering expenses4,237,397 — Proceeds from employee stock purchase plan374,652 — Net cash provided by financing activities5,303,519 28,441,073 Net decrease in cash and cash equivalents(23,261,097)(13,231,069)Cash and cash equivalents at beginning of period59,405,817 72,636,886 Cash and cash equivalents at end of period$36,144,720 $59,405,817 Supplemental disclosures of noncash investing and financing information:Property and equipment in accounts payable/accrued expenses$— $14,983 

The accompanying notes are an integral part of these consolidated financial statements.

123